Atlas
Every compliance team wants to be proactive. They want to spot changes early, assess impact quickly, and act before an investigator raises an issue.
Atlas
The shift from paper to electronic logs (eLogs) and electronic batch records (eBMRs) is accelerating across pharma manufacturing.
Atlas
Repeat FDA violations keep showing up across drug, biologic, and device manufacturers because problems are systemic, including weak quality systems, sloppy data integrity, poor documentation, and inadequate CAPA and training.
Atlas
Between 2024 and 2025, the FDA shifted from pandemic-era stop-start inspection tactics to a sustained, more aggressive, data-driven, and technology-enabled oversight posture for foreign facilities.
Atlas
Across 2024 and 2025 FDA inspections, the biggest documentation failures involve data integrity and poor recordkeeping: missing batch records, altered lab data, weak CAPA investigations, and incomplete deviation files. This post covers what investigators are finding and how to fix it.
Atlas
Weak CAPA and investigation systems drive a high share of Form 483s and warning letters. This guide breaks down why investigations stop at "human error," how regulators read CAPA records, and the specific procedure, RCA, and governance fixes that make the system audit-ready.
Atlas
In May 2025 the FDA expanded unannounced inspections at foreign manufacturing sites. This piece breaks down the six reasons behind the shift, what the agency actually said, the investigator workforce reality, and how pharma and medical device manufacturers should respond.
Atlas
CAPA effectiveness is central to product quality, patient safety, and regulatory compliance in pharma and medical devices. This guide walks through the seven load-bearing CAPA metrics, verification plans, governance layers, and a sample dashboard leaders can adapt.
Atlas
The FDA is increasing inspections of foreign contract manufacturers, often without notice. Investigators focus on quality systems, data integrity, sterility controls, process validation, labs, supplier quality, and complaint handling. This guide breaks down what they look for and how pharma leaders can stay ready.
Atlas
FDA Import Alerts can trigger detention without physical examination and freeze revenue at the border. This guide explains how the framework works, which root causes drive alerts, and the upstream quality and documentation practices manufacturers need to stay off the red list.
Atlas
FDA Form 483 observations and Warning Letters point to the same recurring root causes: data integrity lapses, weak quality systems (CAPA and investigations), incomplete batch records, training gaps, and equipment controls. This post breaks down each category and what QA teams can do about them.
Atlas
Prepare as if inspections are always possible. QA teams must keep documentation current, systems validated, staff trained, and evidence traceable.
Atlas
Model Context Protocol turns ELNs, LIMS, MES, and QMS into discoverable, auditable interfaces for AI agents. For QA teams, it means fewer transcription errors, tamper-resistant audit trails, stronger ALCOA+ provenance, and faster root-cause work during FDA and EMA investigations.
Atlas
Pharma and medical device QA teams still fight version mismatches, manual evidence collation, and slow inspection responses. Model Context Protocol connects AI agents to MES, LIMS, QMS, and document repositories in a governed way, so audit-ready bundles, provenance, and semantic search become standard.
Atlas
AI is a practical capability for quality teams preparing for FDA inspections. Used well, it converts manual document review into reproducible queries, scores CAPA risk, and surfaces recurring observations across sites and suppliers.